Healthcare provider profile · identity verified

Uma Tadepalli, M.D.

Internal Medicine · DURHAM, NC · NPI 1104263672

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	408	104
Amlodipine Besylate	Amlodipine Besylate	344	112
Rosuvastatin Calcium	Rosuvastatin Calcium	291	80
Gabapentin	Gabapentin	223	55
Albuterol Sulfate Hfa	Albuterol Sulfate	184	60
Lisinopril	Lisinopril	173	43
Metoprolol Succinate	Metoprolol Succinate	165	43
Omeprazole	Omeprazole	138	42
Furosemide	Furosemide	136	34
Metformin Hcl Er	Metformin Hcl	136	34
Losartan Potassium	Losartan Potassium	130	34
Carvedilol	Carvedilol	126	30
Trazodone Hcl	Trazodone Hcl	110	23
Jardiance	Empagliflozin	108	23
Fluticasone Propionate	Fluticasone Propionate	104	28
Pantoprazole Sodium	Pantoprazole Sodium	102	35
Spironolactone	Spironolactone	101	27
Hydrochlorothiazide	Hydrochlorothiazide	93	39
Duloxetine Hcl	Duloxetine Hcl	91	19
Mounjaro	Tirzepatide	81	14
Ozempic	Semaglutide	77	24
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	73	15
Metformin Hcl	Metformin Hcl	70	21
Buspirone Hcl	Buspirone Hcl	65	15
Fluoxetine Hcl	Fluoxetine Hcl	64	15
Meloxicam	Meloxicam	60	14
Sertraline Hcl	Sertraline Hcl	60	14
Montelukast Sodium	Montelukast Sodium	59	12
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	55	17
Bupropion Xl	Bupropion Hcl	54	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	53	12
Levothyroxine Sodium	Levothyroxine Sodium	53	17
Eliquis	Apixaban	52	18
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	49	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	48	22
Famotidine	Famotidine	47	suppressed
Ibuprofen	Ibuprofen	47	19
Torsemide	Torsemide	47	suppressed
Potassium Chloride	Potassium Chloride	46	12
Prednisone	Prednisone	46	30
Mirtazapine	Mirtazapine	45	19
Nitroglycerin	Nitroglycerin	45	14
Diclofenac Sodium	Diclofenac Sodium	44	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	43	19
Citalopram Hbr	Citalopram Hydrobromide	42	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	suppressed
Ondansetron Odt	Ondansetron	41	suppressed
Allopurinol	Allopurinol	40	14
Quetiapine Fumarate	Quetiapine Fumarate	40	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	40	18
Clopidogrel	Clopidogrel Bisulfate	39	suppressed
Ezetimibe	Ezetimibe	39	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	39	suppressed
Tramadol Hcl	Tramadol Hcl	39	suppressed
Lidocaine	Lidocaine	36	suppressed
Lamotrigine	Lamotrigine	35	suppressed
Nyamyc	Nystatin	34	suppressed
Valsartan	Valsartan	34	19
Methocarbamol	Methocarbamol	32	14
Donepezil Hcl	Donepezil Hcl	31	suppressed
Januvia	Sitagliptin Phosphate	31	suppressed
Linzess	Linaclotide	30	suppressed
Alendronate Sodium	Alendronate Sodium	29	suppressed
Finasteride	Finasteride	29	suppressed
Clotrimazole	Clotrimazole	28	suppressed
Trulicity	Dulaglutide	27	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	26	suppressed
Farxiga	Dapagliflozin Propanediol	26	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	26	suppressed
Pregabalin	Pregabalin	25	suppressed
Simvastatin	Simvastatin	25	suppressed
Ventolin Hfa	Albuterol Sulfate	25	suppressed
Xarelto	Rivaroxaban	25	suppressed
Risperidone	Risperidone	24	suppressed
Amlodipine-Valsartan-Hctz	Amlodipine/Valsartan/Hcthiazid	23	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	23	suppressed
Symbicort	Budesonide/Formoterol Fumarate	23	suppressed
Arnuity Ellipta	Fluticasone Furoate	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Celecoxib	Celecoxib	20	12
Clonidine	Clonidine	20	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	20	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	20	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Oxycodone Hcl	Oxycodone Hcl	20	suppressed
Topiramate	Topiramate	19	suppressed
Glipizide Er	Glipizide	17	suppressed
Nystatin	Nystatin	16	suppressed
Entresto	Sacubitril/Valsartan	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Atenolol	Atenolol	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Nystop	Nystatin	14	suppressed
Telmisartan	Telmisartan	14	suppressed
Carbamazepine Er	Carbamazepine	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Etodolac	Etodolac	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Abilify Maintena	Aripiprazole	12	suppressed
Bupropion Hcl	Bupropion Hcl	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Clonazepam	Clonazepam	12	suppressed
Metolazone	Metolazone	12	suppressed
Timolol Maleate	Timolol Maleate	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Estradiol	Estradiol	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error